Recently the FDA approved the first drug designed to prevent migraines. The development of medicines designed to block Calcitonin Gene-Related Peptide Receptor (CGRP) has brought forth groundbreaking advancements in the prevention of migrations. Aventiv Research is currently conducting clinical trials on CGRP-blocking migraine prevention drugs.
Approximately 36 million Americans are affected by migraines, luckily, Aventiv offers migraine clinical trials for qualified participants in Columbus, Ohio. More severe than a typical headache, migraine symptoms often include:
Many migraine sufferers struggle with depression, anxiety, and difficulty sleeping in addition to their headache. The attacks often cause them to skip social activities and take time off from work. Aventiv hopes to put an end to constant headaches with migraine clinical trials to support further research and future treatments.
Researchers believe that migraines may be caused by a central nervous system disorder, irregularities with blood vessels in the brain, chemical abnormalities, or genetics. Clinical studies are an important step to understanding the cause and finding a solution to prevent migraines.
If you experience 15 or more days with headache per month, local doctors need your help testing an investigational migraine prevention medication. Qualified participants in this migraine clinical trial must:
Participants in this research study will be seen by a doctor and receive all study-related care, testing and study medication at no cost. Compensation for time and travel may be available.
If you are interested in learning more about this research study, please fill out the volunteer form on this page or call us at 614-501-6164.